Yahoo · Sep 24, 2026
Roivant reports top-line data from IMVT-1402 CLE trial
This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo.
IM
NASDAQ · IMVT
Immunovant, Inc.
Healthcare · Biotechnology
$33.65
Up+$0.11 (+0.33%)
Updated Oct 2, 2026, 4:06 PM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.35B
- P/E ratio
- -9.28
- Dividend yield
- 0.00%
- 52-week range
- $22.79 – $45.42
- Volume
- 1.67M
- Avg. volume
- 1.69M
Price performance · IMVT
IMVT price history
1M range · 0 trading sessions · Daily adjusted prices
IMVT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest IMVT news
The latest Smart Investors Daily articles mentioning IMVT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IMVT research
Overview
Company profile and research snapshot.
Company profile
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $16.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | JP Morgan | Overweight | — |
| Jun 30, 2026 | Citigroup | Buy | — |
| May 26, 2026 | Guggenheim | Buy | — |
| May 22, 2026 | Truist Securities | Hold | — |
| May 21, 2026 | B of A Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 23, 2026
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
Immunovant halts development of its lead drug candidate, imeroprubart, in skin lupus following a trial miss.
Yahoo · Sep 23, 2026
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Immunovant is discontinuing development of IMVT-1402 in cutaneous lupus but will continue to develop the therapy for several other autoimmune diseases.
Yahoo · Sep 23, 2026
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
